- High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I StudyHu, Yongxian; Zhang, Jiqin; Zhang, Mingming; Li, Wei; Wu, Wenjun; Cui, Jiazhen; Wei, Guoqing; Du, Bing; Liu, Mingyao; Huang, He64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
- CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive LymphomaHe, Bailin; Chen, Hong; Deng, Shikai; Li, Chengyao; Xu, Na; Liu, Xiaoli; Zhou, Hongsheng; Liu, Qifa65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALLKang, Liqing; Ma, Jinfeng; Lou, Xiaoyan; Tang, Xiaowen; Xue, Shengli; Chen, Suning; Qiu, Huiying; Miao, Miao; Han, Yue; Wang, Ying; Sun, Aining; Dai, Haiping; Xu, Yang; Li, Limin; Fan, Shengjin; Qian, Chongsheng; Gong, Wenjie; Xu, Mingzhu; Zhou, Haixia; Yao, Zhen65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma
14阅读
